Procept Biorobotics Corp
$ 21.71
-5.73%
29 Apr - close price
- Market Cap 1,310,624,000 USD
- Current Price $ 21.71
- High / Low $ 23.37 / 21.28
- Stock P/E N/A
- Book Value 6.50
- EPS -1.72
- Next Earning Report 2026-04-29
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.12 %
- ROE -0.25 %
- 52 Week High 66.85
- 52 Week Low 19.35
About
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. The company is headquartered in Redwood City, California.
Analyst Target Price
$30.11
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-03 | 2025-11-04 | 2025-07-30 | 2025-04-29 | 2025-02-25 | 2024-10-30 | 2024-08-01 | 2024-05-01 | 2024-02-27 | 2023-11-08 | 2023-07-27 | 2023-04-27 |
| Reported EPS | -0.53 | -0.38 | -0.35 | -0.45 | -0.35 | -0.4 | -0.5 | -0.51 | -0.54 | -0.51 | -0.56 | -0.63 |
| Estimated EPS | -0.3243 | -0.41 | -0.4125 | -0.4913 | -0.34 | -0.49 | -0.52 | -0.56 | -0.44 | -0.51 | -0.57 | -0.58 |
| Surprise | -0.2057 | 0.03 | 0.0625 | 0.0413 | -0.01 | 0.09 | 0.02 | 0.05 | -0.1 | 0 | 0.01 | -0.05 |
| Surprise Percentage | -63.4289% | 7.3171% | 15.1515% | 8.4063% | -2.9412% | 18.3673% | 3.8462% | 8.9286% | -22.7273% | 0% | 1.7544% | -8.6207% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-29 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.55 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PRCT
2026-04-25 05:38:48
Wall Street Zen upgraded PROCEPT BioRobotics (NASDAQ:PRCT) from a "strong sell" to a "sell" rating. This upgrade comes despite mixed analyst coverage overall, with a consensus "Hold" rating and a target price of $40.82. The company recently missed its earnings expectations, reporting an EPS of ($0.53) against an expected ($0.32) and revenue of $76.38M versus $93.7M.
2026-04-24 20:09:05
PROCEPT BioRobotics Chief Strategy and Marketing Officer Pooja Sharma has reported her initial insider holdings. She beneficially owns 87,559 shares of common stock, including restricted stock units that vest over time. Additionally, Sharma holds stock options for 29,615 shares at an exercise price of $25.35 and options for 85,929 shares at an exercise price of $31.92, both with vesting schedules contingent on continued employment.
2026-04-24 16:09:05
Chicago Capital, LLC significantly increased its stake in PROCEPT BioRobotics (NASDAQ:PRCT) by adding 969,592 shares, an estimated $27.32 million investment, during the first quarter of 2026. This move reflects the firm's strategy to acquire shares of PROCEPT BioRobotics, which has seen its stock price decline substantially, yet continues to demonstrate strong growth in procedures and improved EBITDA margins. The company, known for its AquaBeam Robotic System for urologic surgery, is viewed by some as an attractive high-risk, high-reward opportunity for healthcare-savvy investors due to its growth potential and discounted sales multiple.
2026-04-24 12:40:16
TD Cowen has reiterated a Buy rating on Procept BioRobotics (NASDAQ: PRCT) with a $34.00 price target, citing confidence in the company's growth opportunities despite a challenging fourth quarter and recent guidance cut. The firm expects an in-line first quarter, which could boost the stock ahead of its April 29th earnings report. This positive outlook comes amid recent company developments including the international launch of its HYDROS Robotic System and a new board appointment.
2026-04-24 00:38:48
TD Cowen has reiterated a Buy rating on Procept BioRobotics Corp (NASDAQ:PRCT) with a $34.00 price target, citing confidence in the company's growth opportunities despite a challenging fourth quarter. The firm expects an in-line first quarter, which it believes will boost the stock, and anticipates more clarity when the company reports earnings on April 29. This follows recent developments including the international launch of its HYDROS Robotic System in the UK and new board appointments.
2026-04-23 08:39:00
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) has received a consensus "Hold" rating from fourteen brokerages, with an average 1-year price objective of $40.82. The company recently missed earnings expectations, reporting ($0.53) EPS against an anticipated ($0.32) and revenue of $76.38 million versus $93.7 million expected. Despite the earnings miss, significant insider buying activity was noted, with Director Antal Rohit Desai purchasing nearly 100,000 shares.
